Magnetar Financial LLC Makes New Investment in Twist Bioscience Co. (NASDAQ:TWST)

Magnetar Financial LLC bought a new stake in shares of Twist Bioscience Co. (NASDAQ:TWST) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 7,246 shares of the company’s stock, valued at approximately $337,000.

Several other large investors also recently added to or reduced their stakes in TWST. Wilmington Savings Fund Society FSB acquired a new stake in Twist Bioscience during the 3rd quarter valued at $34,000. Van ECK Associates Corp raised its stake in Twist Bioscience by 56.4% during the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock valued at $34,000 after purchasing an additional 267 shares during the period. US Bancorp DE increased its stake in shares of Twist Bioscience by 72.0% in the fourth quarter. US Bancorp DE now owns 1,436 shares of the company’s stock worth $67,000 after acquiring an additional 601 shares during the last quarter. Beaird Harris Wealth Management LLC acquired a new position in shares of Twist Bioscience in the third quarter worth $95,000. Finally, KBC Group NV increased its stake in shares of Twist Bioscience by 71.4% in the fourth quarter. KBC Group NV now owns 2,942 shares of the company’s stock worth $137,000 after acquiring an additional 1,226 shares during the last quarter.

Insider Activity at Twist Bioscience

In related news, insider Dennis Cho sold 806 shares of the stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $49.35, for a total value of $39,776.10. Following the completion of the sale, the insider now owns 112,221 shares in the company, valued at approximately $5,538,106.35. This trade represents a 0.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Emily M. Leproust sold 2,402 shares of the stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $40.91, for a total transaction of $98,265.82. Following the completion of the transaction, the chief executive officer now directly owns 662,692 shares of the company’s stock, valued at $27,110,729.72. This trade represents a 0.36 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 31,552 shares of company stock worth $1,500,289. Company insiders own 3.01% of the company’s stock.

Twist Bioscience Trading Up 2.0 %

Shares of NASDAQ:TWST opened at $42.89 on Friday. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. Twist Bioscience Co. has a 1 year low of $27.41 and a 1 year high of $60.90. The firm has a fifty day moving average price of $45.40 and a 200 day moving average price of $45.23. The stock has a market capitalization of $2.56 billion, a PE ratio of -12.69 and a beta of 2.15.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The business had revenue of $88.70 million during the quarter, compared to analysts’ expectations of $86.96 million. During the same quarter last year, the company earned ($0.75) earnings per share. The firm’s revenue was up 24.1% on a year-over-year basis. Analysts expect that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently weighed in on TWST. JPMorgan Chase & Co. upped their price target on shares of Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a research note on Tuesday, February 4th. Robert W. Baird upped their price target on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 4th. Wolfe Research began coverage on shares of Twist Bioscience in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 price target on the stock. Scotiabank reaffirmed an “outperform” rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Finally, TD Cowen reiterated a “buy” rating and issued a $58.00 price objective on shares of Twist Bioscience in a report on Tuesday, November 26th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $54.40.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.